Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) traded up 0.1% during mid-day trading on Thursday. The company traded as high as $13.6550 and last traded at $13.44. 1,172,683 shares were traded during mid-day trading, an increase of 2,088% from the average daily volume of 53,591 shares. The stock had previously closed at $13.42.
Aerovate Therapeutics Stock Performance
The stock has a market capitalization of $389.56 million, a PE ratio of -4.49 and a beta of 0.95. The stock has a 50-day moving average price of $18.45 and a two-hundred day moving average price of $19.75.
Aerovate Therapeutics Company Profile
Aerovate Therapeutics, Inc was a clinical-stage biopharmaceutical company focused on developing therapies for pulmonary arterial hypertension (PAH) and other serious pulmonary vascular diseases. The company’s lead product candidate was AV-101, an inhaled dry-powder formulation of imatinib intended to target the underlying vascular remodeling associated with PAH.
AV-101 was evaluated in clinical studies, including the IMPAHCT program, for patients with pulmonary arterial hypertension. The company did not have an approved commercial product and operated primarily as a research and development organization serving the biopharmaceutical market.
In 2024, Aerovate reported that the IMPAHCT study did not meet its primary efficacy endpoint and announced plans to discontinue development of AV-101, reduce its workforce and wind down operations while evaluating strategic alternatives.
See Also
- Five stocks we like better than Aerovate Therapeutics
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
